Imbrium Therapeutics Pipeline
Our robust and diversified pipeline of investigational therapy candidates are being evaluated in serious medical conditions.
Preclinical
Phase I
Phase II
Phase III
Registration
CANDIDATE
INDICATION
Tinostamustine Phase II
INDICATION: Oncology
Tinostamustine is a first-in-class, new chemical entity that combines two potentially synergistic mechanisms modes of action, alkylating activity and pan histone deacetylase inhibition (or HDAC inhibition). Tinostamustine is under investigation in patients who have exhausted treatment options (relapsed/refractory malignancies).
Sunobinop Phase I
INDICATION: AUD/IAAC1
Sunobinop is a first-in-class, new chemical entity that potently and selectively activates nociceptin/orphanin-FQ (NOP) receptors. Sunobinop is currently under investigation across a number of potential indications including alcohol use disorder, interstitial cystitis and overactive bladder.
Preclinical
INDICATION: Interstitial Cystitis Pain
Preclinical
INDICATION: Overactive Bladder
Epinephrine film* Phase I
INDICATION: Emergency Treatment of Allergic Reactions (Anaphylaxis)
KL-01401 is a novel film formulation for the emergency treatment of Anaphylaxis Associated with Severe Allergic Reactions. KL-01401 has the potential to be a substantial improvement over existing treatments including epinephrine injection.
1IAAC = Insomnia Associated with Alcohol Cessatio; AUD = Alcohol Use Disorder
*Development Collaboration
The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the investigational agents will successfully complete clinical development or gain approval from the United States Food and Drug Administration or other health authorities.